IgA nephropathy

San Diego, California | April 13, 2026 Travere Therapeutics, Inc. has announced that the U.S. Food and Drug Administration...

Tokyo, Japan, November 26 2025 — Renalys Pharma has announced positive topline results from its Phase III clinical study...

BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...